Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $2.0 million.

  • Nurix Therapeutics' Depreciation & Amortization (CF) fell 15.29% to $2.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $9.2 million, marking a year-over-year increase of 5.35%. This contributed to the annual value of $9.3 million for FY2024, which is 23.70% up from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Depreciation & Amortization (CF) is $2.0 million, which was down 9.55% from $2.2 million recorded in Q2 2025.
  • Nurix Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $2.5 million during Q4 2024, with a 5-year trough of $600,000 in Q2 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $2.1 million, with a median of $2.0 million in 2024.
  • As far as peak fluctuations go, Nurix Therapeutics' Depreciation & Amortization (CF) skyrocketed by 116.67% in 2022, and later decreased by 15.29% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Depreciation & Amortization (CF) stood at $767,000 in 2021, then skyrocketed by 111.08% to $1.6 million in 2022, then rose by 19.46% to $1.9 million in 2023, then soared by 31.80% to $2.5 million in 2024, then dropped by 15.29% to $2.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.0 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.4 million in Q1 2025.